Subscribe
Subscribe for the Newsletter
Mobile Navigation
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Experience
Market Research
Directory
Close
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™
Samsung Biologics
Oct 10, 2025
PR-10-25-NI-11
Press Releases
Biologics - Large Molecule
Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.
Explore
About Us
Nice Insight
That's Nice
Reach Our Team
Contact Us
Advertise
LinkedIn
My Account
Login
Sign up
Subscribe for the newsletter
© 2026 PHARMA'S ALMANAC. All rights reserved.
Privacy Policy
Terms And Conditions
Related Content
Capacity
Is the Bioreactor Arms Race Over?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-01
Sep 1, 2026
Lipase Risk
An Integrated Analytical Approach to Lipase Risk Management in Biologics Development
Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun
Samsung Biologics
PAO-08-26-CL-10
Aug 31, 2026
New Brand
QPharma Builds on a Trusted Legacy to Shape the Future of Complex Drug Delivery
QPharma
PR-08-26-04
Aug 31, 2026
Fun
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
Samsung Biologics
PR-08-26-03
Aug 31, 2026
New Facilities
SK pharmteco Marks Construction Progress with Ribbon Cutting for Two Advanced Manufacturing Facilities at Swords, Ireland Campus
SK pharmteco
PR-08-26-02
Aug 18, 2026
Prevention
Preventive Therapeutics Beyond Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-13
Aug 18, 2026
Masked Antibody
Expanding the Oncology Therapeutic Window Through Masked Antibody Technology
Sean McCarthy, Ph.D; David Alvaro, Ph.D.
CytomX Therapeutics
PAO-08-26-CL-09
Aug 14, 2026
Self-Injection
The Quiet Revolution in How We Take Our Medicine
Ravi Kumar
OneSource Specialty Pharma
PAO-08-26-CL-06
Aug 6, 2026
Critical Materials
Securing Critical Materials for Resilient Biopharmaceutical Manufacturing
Pharma's Almanac
PAO-08-26-PA-04
Aug 6, 2026
Cell Therapy
NueCell Bio Launches as a New Translational Partner to Accelerate Cell Therapies from Discovery into GMP Manufacturing
NueCell Bio
PR-08-26-01
Aug 5, 2026
Vaccines
The Next Generation of Vaccine Platforms
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-01
Aug 3, 2026
AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19
Jul 20, 2026
Previous slide
Next slide
